CGON

$74.71-$2.28 (-2.96%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$6.8B

89M shares

52-week range

$24.85 – $79.39

91% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change+$37.54

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$11M	+292.5%	$-2.75	$-2.93–$-2.46	—	12
2027	$85M	+669.5%	$-2.82	$-3.65–$-2.13	—	11
2028	$453M	+432.7%	$-0.08	$-1.14–$0.90	—	11
2029	$961M	+112.1%	$3.28	$0.66–$7.03	22.8×	4

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.66	$-0.90	-35.5%
2026-05-08	$-0.58	$-0.71	-22.4%
2026-02-27	$-0.61	$-0.51	+16.4%
2025-11-14	$-0.56	$-0.57	-2.0%
2025-08-08	$-0.49	$-0.54	-10.2%
2025-05-13	$-0.39	$-0.45	-15.4%
2025-03-28	$-0.41	$-0.48	-17.1%
2024-08-08	$-0.42

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CGONCG Oncology Inc.	$74.71	-2.96%	$6.6B	—
AAPGAscentage Pharma Group International	$19.00	+0.16%	$1.8B	—
APGEApogee Therapeutics, Inc.	$134.45	-0.07%	$8.3B	—
CELCCelcuity Inc.	$86.60	-5.95%	$4.2B	—
CNTACentessa Pharmaceuticals plc	$40.50	+0.00%

CG Oncology, Inc. Common stock

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

www.cgoncology.com

Employees: 142
IPO / List date: Jan 25, 2024
HQ: DALLAS, TX

Held by traders on TradeandTell

No one on the platform currently holds CGON.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2025-06-30	46,100	$1.2M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CGON yet.

$CGON chatter on StockTwits

Squeezy@TheRealShortSqueezyBullish12h
$ONCY : FDA Momentum Keeps Building 🧬 Oncolytics Biotech is entering an important stretch for pelareorep with strong clinical data and growing FDA support. 🔹 3 FDA Fast Track Designations across three cancer programs. 🔹 Colorectal cancer study showed a 33% response rate vs. ~10% historically, more than 3X higher. 🔹 Patients went 16.6 months without cancer worsening vs. 5.7 months, with median survival of 27 months vs. 11.2 months. 🔹 Colorectal cancer alone represents an estimated $3B–$5B annual opportunity. 🔹 Pelareorep has been evaluated in 1,300+ patients, with collaborations involving Roche, Pfizer, Incyte and others. 🔹 New U.S. patent protection extends through 2044. 📊 TECHNICAL SETUP: ONCY defended $0.77 support and is curling higher. Key levels: $0.85 → $0.93 → $1.08 → $1.18 → $1.30. Communicated Disclaimer: https://stockresearchtoday.com/oncy/ Sector Peers: $REPL $GNLX $CADL $CGON
View on StockTwits ↗
NeOnc Technologies@NeOnc_Technologies14h
The latest PR highlights more than clinical results; it reinforces the scientific rationale behind NEO100's development. One of the biggest challenges in brain cancer isn't identifying promising therapies, but delivering them across the blood-brain barrier to reach the tumor. NEO100 was specifically designed as an intranasal therapy to bypass that barrier, representing a different approach to drug delivery than conventional systemic administration. That strategy reflects NeOnc's focus on addressing one of the fundamental limitations in treating brain tumors. Innovation in brain cancer isn't only about discovering new molecules; it's also about finding better ways to deliver them where they're needed most. $NTHI $SMMT $CGON $MRK
View on StockTwits ↗
NeOnc Technologies@NeOnc_Technologies1d
$NTHI The latest PR reinforces that clinical development isn't defined by a single number; it's built through consistent evidence over time. While NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), the study also reported a median overall survival of 26.1 months. The evidence continues to evolve. With five patients still receiving treatment, the clinical dataset is still growing, providing additional insight into NEO100's long-term clinical profile. As therapies like temozolomide have shown over time, lasting clinical impact is built through accumulating evidence, not a single readout. $NTHI $MRK $EXEL $CGON
View on StockTwits ↗
Lanuchbox@Market_Pulse_Report2d
$CGON
View on StockTwits ↗
Lanuchbox@Market_Pulse_Report2d
$CGON Great video overview explaining what is going on here!!! https://youtu.be/7uzSrCMVv_0?si=8y6oJGsaRkVEbCrm
View on StockTwits ↗
ET Alpha@ETAlpha6d
$CGNX is trading strong around $66.89 right now! $CGON is trading strong around $75.10 right now! Goldman Sachs hiked Cognex to $91 alongside bullish bumps from Cantor, Needham, and Truist; meanwhile, Truist and Piper Sandler pushed CG Oncology targets up to $85. With institutional upgrades rolling in, avoid chasing green candles blindly and scale into key support dips! Are these target hikes setting up the ultimate breakout rally for both names?
View on StockTwits ↗
Dan@forprofit12Aug 5
$CGON did management forget they promised us data in q2. We are done with 1/3 of q3. Where is the data?
View on StockTwits ↗
Grinding10@Grinding10Aug 4
$CGON really don’t need to draw lines; it’s $50 to $75 until u get an approval or not; Straight up or down at that point 🤷‍♂️Ever been in a bio?
View on StockTwits ↗
黃融融@ron1013Aug 2
@oceanviewhi future compepitor $cgon
View on StockTwits ↗
WE DRAW LINES@AC_TRADERAug 2
$CGON Levels made with @TrendSpider https://share.trendspider.com/chart/CGON/7594bh90rt
View on StockTwits ↗
Quantumup@QuantumupJul 29
H.C. Wainwright reiterated $CGON and said -- Yesterday, CG Oncology published the results of their Phase 3 BOND-003 data in high-risk BCG unresponsive NMIBC in Lancet Oncology. $JNJ $URGN TARA TYRA MRK IBRX Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2082431334996185513?s=20
View on StockTwits ↗
M@justiceforb_85Jul 23
$CGON patiently waiting.
View on StockTwits ↗
Nosh@NoshJul 21
$CGON Been in and out of this one a few times but that dip to almost $50 ($53) was entry and missed it...watching again.
View on StockTwits ↗
Grinding10@Grinding10Jul 20
$CGON this is really becoming a waste of fucking time
View on StockTwits ↗
Quantumup@QuantumupJul 16
H.C. Wainwright reiterated $URGN Buy-$45 and said -- New patent claims may extend exclusivity until 2044, whereas our model assumes generic erosion starting in 2031—driving massively material upside to our current forecasts. $CGON $TYRA MRK LLY IBRX Her's what else H.C. Wainwright said: https://x.com/Quantumup1/status/2077754507539218549?s=20
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.